Clinical trial · Interventional
Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy
Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are: * Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy? * How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment? * Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks. * Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle. * Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coenzyme Q 10 | Dietary Supplement | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CoQ10 group
- description
- Participants in this arm will receive standard weekly paclitaxel chemotherapy (80 mg/m²) for twelve weeks in combination with Coenzyme Q10 supplementation at 200 mg twice daily. The purpose of this arm is to evaluate the effect of Coenzyme Q10 on chemotherapy-induced peripheral neuropathy, fatigue, pain, and related serum biomarkers.
- interventionNames
- Dietary Supplement: Coenzyme Q 10
- Drug: Paclitaxel
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- Participants in this arm will receive standard weekly paclitaxel chemotherapy (80 mg/m²) for twelve weeks without Coenzyme Q10 supplementation. This arm serves as a comparator to evaluate the effects of Coenzyme Q10 on chemotherapy-induced peripheral neuropathy, fatigue, pain, and related serum biomarkers.
- interventionNames
- Drug: Paclitaxel
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18 years or older with newly diagnosed breast cancer. * Chemotherapy-naïve (have not received prior chemotherapy). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion Criteria: * Pregnancy or breastfeeding. * Severe cardiovascular disease (left ventricular ejection fraction \<55%). * Hereditary muscle disorders. * Diabetes mellitus or history of alcoholism. * Thyroid dysfunction. * History of allergy to Coenzyme Q10 or related compounds. * Advanced liver disease (liver enzyme elevation \>3× upper limit of normal or cirrhosis). * Chronic kidney disease (CKD), defined as estimated glomerular filtration rate \<60 mL/min/m².
References
Publications (0)
Data not yet available